Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 2/20 | 0.56 |
| ▸ | RARB | P10826 | 2/20 | 0.56 |
| ▸ | RARG | P13631 | 2/20 | 0.56 |
| ▸ | WDR5 | P61964 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107399 | 0.86 | NR1H4 (0.53) | RARARARBRARGWDR5CYP3A4 | |
| SCHEMBL1190600 | 0.85 | CYP2C9 (0.44) | RARARARBRARGCYP3A4CYP1A2 | |
| SCHEMBL2773345 | 0.84 | RARA (0.61) | RARARARBRARGWDR5CYP3A4 | |
| SCHEMBL31325762 | 0.84 | RARA (0.73) | RARARARBRARGWDR5CYP3A4 | |
| SCHEMBL1421835 | 0.84 | RARA (0.73) | RARARARBRARGWDR5CYP3A4 | |
| SCHEMBL10428428 | 0.83 | NR1H4 (0.48) | RARARARBRARGTSHRALDH1A1 | |
| SCHEMBL5027170 | 0.83 | MAPT (0.58) | RARARARBRARGWDR5CYP3A4 | |
| SCHEMBL22601523 | 0.83 | RARA (0.56) | RARARARBRARGWDR5CYP3A4 | |
| Hydrochloric Acid SCHEMBL9131236 | 0.83 | RARA (0.71) | RARARARBRARGWDR5TSHR | |
| SCHEMBL8839075 | 0.82 | RARA (0.44) | RARARARBRARGWDR5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259163-B2 | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-21 | — | — | US | disclosed |
| EP-1440069-B1 | 4-(6-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20050043390-A1 | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | US | disclosed |
| EP-1440069-A1 | 4-(6-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037895-A1 | 4-(6-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
| US-6368608-B1 | SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHE DERMATOLOGIQUES GALDERMA (C.I.R.D.) (FR) | 2002-04-09 | — | — | US | disclosed |
| US-6162445-A | Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-19 | — | — | US | disclosed |
| US-5869067-A | TREATING DERMATOLOGICAL DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1999-02-09 | — | — | US | disclosed |
| US-5753239-A | Bi-aromatic compounds and pharmaceutical and cosmetic compositions | CENTRE INTERNATIONAL DE RECHERCHES DEMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1998-05-19 | — | — | US | disclosed |
| US-5716624-A | USEFUL FOR TREATING DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, OPTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS/DISORDERS | C.I.R.D. GALDERMA (FR) | 1998-02-10 | — | — | US | disclosed |
| US-5439925-A | Skin disorders, rheumatic diseases | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-08-08 | — | — | US | disclosed |
| US-5428052-A | Classifiable as retinoids; skin disorders, corneopathy | CENTRE INTERNATIONALE DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) | 1995-06-27 | — | — | US | disclosed |
| US-5387594-A | Administering for topical and systemic treatment of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-02-07 | — | — | US | disclosed |
| US-5288744-A | Tetramethyltetrahydronaphthyl benzothiazole for treating skin disorders | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) | 1994-02-22 | — | — | US | disclosed |
| US-5260295-A | Retinoic acid derivatives, cosmetics, skin disorders | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) | 1993-11-09 | — | — | US | disclosed |
| US-5059621-A | Treatment of dermatologic ailments linked to keratinization disorder | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) | 1991-10-22 | — | — | US | disclosed |
| US-4927835-A | ANTIPYRETICS | NIPPON SHINYAKU CO., LTD. (JP) | 1990-05-22 | — | — | US | disclosed |
| US-4920140-A | Skin disorders | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1990-04-24 | — | — | US | disclosed |
| EP-0331195-A2 | Acylphenol derivatives | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4740519-A | Benzo (b) thiophene carboxylate derivatives and pharmaceutical compositions | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1988-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043390-A1 | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors | NR1H3, NR1H2, NR1I3 | RARA 1396/4885RARB 1180/4885RARG 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.